BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, East Asia, and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company serves doctors, hospitals, and medical centers in the field of psychiatry. The company was founded in 2003 and is headquartered in Jerusalem, Israel. Show more
Location: 16 Hartum St, Jerusalem, 9777516, Israel | Website: https://www.brainsway.com | Industry: Medical Devices | Sector: Healthcare
Market Cap
296.4M
52 Wk Range
$7.06 - $16.00
Previous Close
$15.68
Open
$15.60
Volume
73,661
Day Range
$15.43 - $16.06
Enterprise Value
223.1M
Cash
78.0M
Avg Qtr Burn
N/A
Insider Ownership
6.40%
Institutional Own.
31.07%
Qtr Updated
06/30/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|